$MDGL

B.Riley reiterated a Buy rating and $670 price target on Madrigal Pharmaceuticals (MDGL) ahead of Q3 earnings, citing U.S. Rezdiffra sales expected above consensus. Analysts highlight strong sales growth and potential upside. MDGL shares are down 26% YTD but trade below Fair Value. The company's market cap is $9.96B, and it maintains a 91% gross profit margin. Multiple analysts have recently adjusted their ratings and targets for MDGL.

UBS raised its price target for Madrigal Pharmaceuticals (MDGL) to $735 from $669, citing a higher probability of success for its F4 program. The stock is currently trading at $452.12, down 22% year-to-date, but analysts maintain a Strong Buy consensus. The company reported Q2 2026 net sales of $364.3 million for Rezdiffra, up 71% year-over-year, but faced a wider net loss and rising expenses. Multiple analysts have adjusted their price targets and ratings for MDGL.

Madrigal Pharmaceuticals (MDGL) published a secondary analysis from its Phase 3 MAESTRO-NASH trial, showing Rezdiffra's effectiveness across genetic variants in MASH patients. The study found consistent fibrosis improvement and MASH resolution in treated groups. The company plans to consult with the FDA on a Phase 2 combination trial with Rezdiffra and MGL-0795. Rezdiffra is approved for MASH treatment and is being tested for cirrhosis.

Goldman Sachs initiated coverage on Madrigal Pharmaceuticals (MDGL) with a Buy rating and $704 price target. The company's Rezdiffra drug generated $1.3B in 12-month revenue with 91% gross margins. Q2 2026 revenue grew 71% YoY to $364.3M, exceeding estimates. Analysts maintain positive ratings despite net losses and rising expenses.

Analysts updated ratings and price targets for several companies. Citi downgraded Dropbox to sell, reducing its target to $29. Arete Research downgraded Etsy to neutral, lowering its target to $81. Goldman Sachs initiated coverage of Madrigal and Revolution with buy ratings and targets of $704 and $267, respectively. Meta was upgraded to buy by President Capital, which raised its target to $897. Paychex was upgraded to neutral by JP Morgan, which raised its target to $115.

Sibold William John (President and CEO) sold 11,583 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $538.65 ($527.88–$546.38, $6.24M total) across 24 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.

Kelley Shannon T (General Counsel) sold 664 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $514.97 ($0.34M total) on 2026-08-17.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors CONSHOHOCKEN, Pa., August 12, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steato

Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.

A roundup of Tuesday Wall Street analyst actions included Deutsche Bank upgrading Palantir to Buy and keeping a $200 target, and Wells Fargo initiating APi Group at Overweight with a $53 target. Other calls covered CoreWeave, Micron, Walmart, Nike, Apple, and SK Hynix, with multiple price targets and rating changes ahead of earnings for some names.